• Vir Biotechnology struck a collaboration and license deal with Gilead to discover three dual-masked T-cell engager candidates for solid tumors.
• Gilead gets exclusive rights to nominate, develop, manufacture, and commercialize the programs.
• Vir will lead discovery and optimization, using its dAIsY platform and PRO-XTEN masking technology.
• Deal terms include $90 million upfront, including $65 million cash and a $25 million equity investment at a 30% premium.
• Vir is eligible for up to $45 million in near-term preclinical milestones, up to $1.74 billion in additional milestones, and tiered royalties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014783426) on October 14, 2026, and is solely responsible for the information contained therein.